Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-G-CAR.BiTE allogeneic γδ T cells
- Development stage
- Phase 2
- Lead developer
- Ever Supreme Bio-Technology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
CAR001 is an investigational allogeneic cell therapy developed by Ever Supreme Bio Technology. It consists of Vδ2 γδ T cells engineered via mRNA electroporation to express a nanobody-based chimeric antigen receptor (CAR) targeting HLA-G, a human leukocyte antigen that acts as an immune checkpoint in solid tumors. Additionally, the cells are engineered to secrete a bispecific T-cell engager (BiTE) targeting PD-L1 and CD3ε. This dual-targeting approach is designed to overcome immune escape mechanisms in the tumor microenvironment. CAR001 is currently being evaluated in Phase I/IIa clinical trials for relapsed or refractory solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), and glioblastoma (GBM).
- Other names
- HLA-G-CAR.BiTE allogeneic gamma-delta T cellsCAR001 allogeneic γδ T cells
02
Targets
HLA-G (Human leukocyte antigen G)CD3 (T-cell surface glycoprotein CD3)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on HLA-G-CAR.BiTE allogeneic γδ T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-G-CAR.BiTE allogeneic γδ T cells.